当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
KOVALTRY, Antihemophilic Factor (Recombinant), Full Length
申请企业
Bayer HealthCare LLC
药品名称
KOVALTRY, Antihemophilic Factor (Recombinant), Full Length
承诺描述
Collect additional safety and efficacy information of KOVALTRY in patients with hemophilia A in an extension clinical study under Protocol 13400 “A multicenter Phase III uncontrolled open-label trial to evaluate safety and efficacy of BAY 81-8973 (KOVALTRY) in children with severe haemophilia A under prophylaxis therapy”